Top of the morning to you, and a fine one, it is. Despite another round of overcast skies enveloping the Pharmalot campus, we are maintaining a stiff upper lip and a sunny outlook. After all, as the Morning Mayor taught us: Every new day should be unwrapped like a precious gift. While you tug on the ribbon, we will fire up the coffee kettle for another cup of stimulation. Meanwhile, here are a few items of interest to stimulate your own neurons. Hope your day is successful and, as always, please do keep in touch.

Another, less likely victim of the outbreak: India’s pharmaceutical industry, The South China Morning Post explains. India imports nearly 70% of its raw materials and active ingredients from China, about $4.5 billion each year. Since 2015, pharmaceutical ingredients have been among India’s top 10 imports from China and a sizable chunk of these were used in the $19.1 billion worth of pharmaceutical products that the latter exported last financial year, according to official figures.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy